AstraZeneca and Daiichi Sankyo Team with Summit to Test Datroway-Ivonescimab Combo in TNBC
AZN is trading near its 52-week low of $146.1 (8.2% above the low).
Summary
AstraZeneca and Daiichi Sankyo have entered a clinical trial collaboration with Summit Therapeutics to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types, beginning with a Phase 3 trial in first-line triple-negative breast cancer (TNBC). Each company will contribute its respective compound, with AstraZeneca or Daiichi Sankyo sponsoring the trials and all three sharing costs. This expands Datroway's development into a novel combination with a potential first-in-class bispecific antibody, and for Summit it marks entry into breast cancer. The collaboration follows Datroway's recent EU approval in first-line metastatic TNBC and builds on AstraZeneca's ADC strategy. No financial terms were disclosed, but the move signals confidence in the combination's potential across lung and breast cancers.
Updates
· SEC 6-K — The 6-K attaches the press release announcing the collaboration.
At the time of this announcement, AZN was trading at $158.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $244.6B. The 52-week trading range was $146.10 to $212.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.